Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q2 2021 · 10-Q
Revenue$100.00K$100.00K— vs Q2 2020 Net Income-$7.14M-$7.14MN/M vs Q2 2020 EPS Diluted-$0.52-$0.52N/M vs Q2 2020 Operating Income-$7,137,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-7137.0%
Net margin-7136.0%
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end